



# Neuro-SysMed

# Newsletter

Issue 1, 2023, May

## DIRECTORS COMMENTS

Dear all

With the summer just around the corner, we can reflect on the progress and accomplishments we have made during the first half of 2023 with great satisfaction. Our collective efforts have led to the initiation of no less than three new phase II trials, N-DOSE, N-DOSE\_AD and NORSEMAN. Common thread to all three trials is one of our signature interventions at Neuro-SysMed – NAD-replenishment therapy – which is now expanding to include Alzheimer's disease and progressive multiple sclerosis.

Furthermore, we are gearing up to a significant milestone – starting a phase II trial of NAD-replenishment therapy for atypical parkinsonian syndromes, including PSP, MSA, and CBS. This will be Norway's first ever therapeutic trial for these rare and profoundly debilitating diseases, and one of only a handful worldwide.

However, NAD-replenishment represents just one of the many innovative and exciting approaches being explored at Neuro-SysMed. Recent groundbreaking findings, to which alumni scientists from our very own MS group played a vital role, strongly suggest that Epstein Bar virus (EBV) is a key trigger for MS. Inspired by these discoveries, we are initiating a first-of-its-kind trial of antiviral therapy for MS, planned to start later this year, and the MS group have submitted an ambitious and strong application for European funding. Additionally, our ALS team just embarked on an exciting and crucial study to assess the effects of respiratory support intervention on the quality of life of individuals with ALS. This endeavor highlights our commitment to addressing the diverse needs of our patients.

We have also had remarkable success in securing external funding, with two major highlights being Bettina Husebø, who was awarded the ERC Consolidator Grant, and Kristina Xiao Liang, who has been granted substantial support from the POLG Foundation. Join us in congratulating Bettina and Kristina on their remarkable accomplishments. We salute you!

As always, we are thrilled and privileged to be working alongside such an exceptionally skilled, ambitious, and determined team. Your dedication and knowledge continue to propel us forward, making these remarkable achievements possible. As we approach the summer season, we extend our warmest wishes to each of you for a pleasant and rejuvenating break.

Best regards from  
Kjell-Morten Myhr and Charalampos Tzoulis

A CENTRE FOR CLINICAL  
TREATMENT RESEARCH



## NEW ANNUAL REPORT

Make sure you don't miss the Neuro-SysMed Annual Report 2022, with lots of information on our research, organization, activities and people.

You can find it online for downloading on [this webpage](#), or you can drop in on our office to get a printed copy.



Neuro-SysMed



ANNUAL REPORT 2022


A centre for clinical treatment research  
on neurological diseases

## RECENT PUBLICATIONS

2023 has kicked-off with a wide range of publications from our groups. We are now starting to see more publications stemming from our clinical trials, with follow-up articles focusing on in-depth bioinformatics and molecular biology analyses. A good example is this publication from the PD node.

### Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease

A recent Neuro-SysMed article in *iScience* by Gaare et al. suggests that Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. Replenishing nicotinamide adenine dinucleotide (NAD) via supplementation of nicotinamide riboside (NR) has been shown to confer neuroprotective effects in models of aging and neurodegenerative diseases, including Parkinson's disease (PD). Although generally considered safe, concerns have been raised that NR supplementation could impact methylation dependent reactions, including DNA methylation, because of increased production and methylation dependent breakdown of nicotinamide (NAM). We investigated the effect of NR supplementation on DNA methylation in a double blinded, placebo-controlled trial of 29 human subjects with PD, in blood cells and muscle tissue. Our results show that NR had no impact on DNA methylation homeostasis, including individuals with common pathogenic mutations in the MTHFR gene known to affect one-carbon metabolism. Pathway and methylation variance analyses indicate that there might be minor regulatory responses to NR. We conclude that short-term therapy with high-dose NR for up to 30 days has no deleterious impact on methylation homeostasis.



- No change in global DNA methylation after 30 days of NR 1000mg/day
- NR may induce minor regulatory responses in DNA methylation
- DNA methylation is not affected by MTHFR genotype

### Other recent publications from the last 3 months

[Treatment of motor symptoms in Parkinson's disease.](#) Dietrichs E et al. *Tidsskr Nor Laegeforen.* 2023 May 4;143(7). doi: 10.4045/tidsskr.22.0804. Print 2023 May 9. PMID: 37158528 English, Norwegian.

[Norwegian version of the Edinburgh cognitive and behavioural ALS screen: Construct validity, internal consistency, inter-rater, and test-retest reliability.](#) Taule T et al. *PLoS One.* 2023 May 4;18(5):e0285307. doi: 10.1371/journal.pone.0285307. eCollection 2023. PMID: 37141321

[Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease.](#) Tuominen JA et al. *Parkinsonism Relat Disord.* 2023 May;110:105389. doi: 10.1016/j.parkreldis.2023.105389. Epub 2023 Mar 31. PMID: 37027994

[POLG genotype influences degree of mitochondrial dysfunction in iPSC derived neural progenitors, but not the parent iPSC or derived glia.](#) Hong Y et al. *Exp Neurol.* 2023 Apr 25;365:114429. doi: 10.1016/j.expneurol.2023.114429. Online ahead of print. PMID: 37105450

[Robot-assisted investigation of sensorimotor control in Parkinson's disease.](#) Tamilselvam YK et al. *Sci Rep.* 2023 Mar 23;13(1):4751. doi: 10.1038/s41598-023-31299-z. PMID: 36959273

[A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.](#) Erikstad KI et al. *Eur J Neurol.* 2023 Jun;30(6):1727-1733. doi: 10.1111/ene.15786. Epub 2023 Mar 26. PMID: 36912432

[Predictors of hospitalization due to infection in rituximab-treated MS patients.](#) Karłowicz JR et al. *Mult Scler Relat Disord.* 2023 Mar;71:104556. doi: 10.1016/j.msard.2023.104556. Epub 2023 Feb 11. PMID: 36842313

[Classification and staging of Parkinson's disease using video-based eye tracking.](#) Brien DC et al. *Parkinsonism Relat Disord.* 2023 May;110:105316. doi: 10.1016/j.parkreldis.2023.105316. Epub 2023 Feb 8. PMID: 36822878

[En mann i 50-årene med nærbesvimelser og vedvarende svimmelhet.](#) Nes MS et al. *Tidsskr Nor Laegeforen.* 2023 Feb 20;143(3). doi: 10.4045/tidsskr.22.0092. Print 2023 Feb 21. PMID: 36811431. Norwegian.

[Altered transcriptome-proteome coupling indicates aberrant proteostasis in Parkinson's disease.](#) Dick F et al. *iScience.* 2023 Jan 4;26(2):105925. doi: 10.1016/j.isci.2023.105925. eCollection 2023 Feb 17. PMID: 36711240

[Interferon  \$\beta\$ 1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis.](#) Lie IA et al. *Mult Scler Relat Disord.* 2023 Feb;70:104530. doi: 10.1016/j.msard.2023.104530. Epub 2023 Jan 21. PMID: 36701908

[White matter hyperintensity burden predicts cognitive but not motor decline in Parkinson's disease: results from the Ontario Neurodegenerative Diseases Research Initiative.](#) Carvalho de Abreu DC et al. *Eur J Neurol.* 2023 Apr;30(4):920-933. doi: 10.1111/ene.15692. Epub 2023 Feb 14. PMID: 36692250



# LAUNCH OF NEW TRIALS

We are happy to announce startup of new trials!

## The Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial (NORSEMAN)

This trial was launched in May 2023 – aiming at reducing disease progression in progressive multiple sclerosis (PMS). Patients will be randomized for 1000 mg nicotinamide riboside (NR) or placebo for 30 months.

Evidence suggest that mitochondrial dysfunction occurs in the brain of patients with MS and may play a particularly important role in the neurodegenerative processes underlying PMS. In this trial, we will evaluate if oral administration of the NR (supplied by Elysium) will increase cerebral NAD levels and improve mitochondrial function, and ameliorate or rescue neuronal dysfunction and death in MS. This, in turn, will hopefully result in improved clinical symptoms and delay disability progression.

The coordinating investigator is Dr. Kristin Varhaug, and the study nurses are Randi Haugstad and Reidun Waaler. The Neurology Departments in Stavanger, Haugesund and Førde will be recruited for participation.



## The FlowOx-MS study

This was launched in May 2023 – aiming at reducing spasticity in patients with multiple sclerosis (PMS).

Patients will be randomized for active therapy or placebo for one month, and further followed for another five months during open label active therapy. The FlowOx device applies pulsed negative pressure on the legs, improving blood flow in patients with intermittent claudication. A recent pilot study at Neuro-SysMed suggested that MS patients experienced relief of spasticity and pain during the use of FlowOx. The mode of action is unknown, but it is suggested that the effect mechanisms involve modulation of signalling at spinal cord level, leading to reduced spasticity.

The coordinating investigator is Dr Kjell-Morten Myhr, and the study nurses are Randi Haugstad and Jorunn Vik. Three other study sites in Sweden and Denmark are also recruiting patients.

## The N-DOSE and N-DOSE\_AD studies: dose optimisation trials of nicotinamide riboside in Parkinson's disease and Alzheimer's disease

These randomized, double-blinded, placebo-controlled phase II trials were commenced in January 2023 with the primary objective to determine the Optimal Biological Dose (OBD) of nicotinamide riboside (NR) for Parkinson's and Alzheimer's disease. This is defined as the dose required to achieve maximal cerebral NAD increase, maximal impact on cerebral metabolism, or maximal proportion of responders among the participants. Individuals with PD (n = 80) and AD (n=80) will be randomized in a 1:1:2 ratio to three groups: placebo, 1000 mg NR daily, or a dose escalation group starting with 1000 mg daily and escalate to 2000 mg and 3000mg at one-month intervals. Measures will include clinical, neuroimaging (31P-MRS, FDG-PET), molecular, and biochemical endpoints. Study duration will be three months.

Coordinating investigators are Dr. Haakon Berven and Dr. Ragnhild Eide Skogseth, and the study nurses are Erika Sheard, Mona Søgner, Solveig af Geijerstam, Therese Vetås, Kristina Skeie, Lone Birkeland Johansen.



## The ALS LTMV study: effects of long-term ventilation support on the quality of life of ALS patients and their families

The ALS LTMV study was initiated in April 2023. The aim of the ALS LTMV study is to increase the knowledge on how life-sustaining ventilator support with non-invasive ventilation (NIV) or tracheostomy invasive ventilation (TIV) affects the quality of life of ALS patients, their life partners and children, in Norway. The results from the study will provide crucial information for clinicians and patients on one of the most difficult ethical issues of ALS treatment. Moreover, we anticipate that this information will facilitate a shared decision-making process, weighing benefits and disadvantages in a wider perspective. The ALS LTMV study is an observational clinical trial, where the quality of life will be assessed in ALS patients receiving NIV or TIV.

Coordinating investigator is Dr Tale Bjercknes and the study nurses are Gunvor Norstein, Marit Renså, Synnøve Bartz-Johanessen, and Mari Klauset Holtom. The study is a collaboration with the Department of Pulmonology.



## The NADbrain study: a pharmacokinetic study of NAD-replenishment in human blood and brain

The NADbrain study was launched in January 2023. This trial will determine the optimal dosing regimen of NAD-replenishment therapy (NRT), including dose size and frequency, by performing a parallel assessment of NRT pharmacokinetics in the blood and brain of healthy human subjects and subjects with Parkinson's disease (PD). A total of 6 healthy individuals (3 men and 3 women) and 10 individuals with PD (5 men and 5 women) will undergo repeated blood sampling and 31P-MRS brain scans for two 20-day periods, each of which will start with 8 days of daily intake of NR 600mg x 2, or NMN 600mg x 2.

Coordinating investigator is Dr Christian Dölle and the study nurses are Erika Sheard, Mona Søgner, Solveig af Geijerstam, and Therese Vetås.





## INTERNATIONAL GRANTS

Congratulations to Bettina Husebø and Kristina Xiao Liang with international grants!

Competing with over two thousand applicants, **Bettina Husebø** is among the 321 researchers who have been awarded the ERC Consolidator Grant 2022 from the European Research Council, ERC. This means that her innovative research project receives two million euros in funding, or around NOK 23 million over five years. Professor Husebø will lead the project 5-D: Decoding Death and Dying in people with Dementia by Digital thanotyping.

Husebø focuses in particular on people with dementia and issues relevant for this patient group. In this project, her group will study how assistive technology can be used to recognize symptoms among people with dementia who are near the end of life. By collecting data from nursing home patients, Husebø wants to develop methods and tools that can provide a more precise understanding of pain and symptoms at the end of life. "Almost 40 per cent of people with dementia die unexpectedly", Bettina Husebø points out.

In this research project, Husebø will use so-called 5D technology to monitor the patients' pain and symptoms, behavioral changes/psychological symptoms and changes in oral patterns. The aim is to be able to better predict when the patients have reached the "point of no return", using advanced data sets.

[Read more about the project and the grant here.](#)



**Kristina Xiao Liang** has been granted support from the [POLG Foundation](#) for her project Stem Cell Research for Drug Discovery to treat POLG Disease. Liang is co-node leader for the Cell Models Node at Neuro-SysMed, as well as a senior researcher and team leader in the Mitochondrial Stem Cell Research group. She is an expert in induced pluripotent stem cell (iPSC) derived models of neurological disease, including 2D and 3D culture modes.

The mission of The POLG Foundation is to support and accelerate research to find effective treatments and a cure for PolG mitochondrial disorders. PolG disease is a genetic disorder that robs the body's cells of energy, in turn causing progressive multiple organ dysfunction and failure. One might compare it to having a faulty battery that never fully recharges and is in a constant state of depletion. The disease is uncommon so no one knows how many patients there are. But PolG research could affect everything from Parkinson's to cancer.

# UPCOMING NEURO-SYSMED EVENTS

## FALCH LECTURE 2023, MAY 24 - ALBERTO ASCHERIO

This month's Neuro-SysMed seminar is combined with the Falch Lecture - with speaker Professor Alberto Ascherio from the Harvard T.H. Chan School of Public Health and Harvard Medical School.

Title: *The Epstein-Barr virus as the leading cause multiple sclerosis and the possible viral etiology of other neurodegenerative diseases*


Professor Ascherio will review the data demonstrating that MS is a rare complication of infection with the Epstein-Barr virus (EBV), focusing on the recent investigation among over 10 million active-duty military personnel that provides virtually conclusive proof of causality. Further, he will briefly discuss the potential underlying mechanisms, and provide an epidemiological perspective on the potential role of infections in Alzheimer disease and other neurodegenerative conditions.

**Register here.** Deadline with lunch is May 19 at 11:00 AM.

**Time:** Wednesday May 24, 2023 at 11:30-13:00 (incl. optional lunch from 11:30-12:00)

**Where:** Auditorium in Armauer Hansens Hus.

**Abstract:** [is available here.](#)



## NEURO-SYSMED SEMINAR JUNE 21 - GONZALO SANCHEZ NIDO

This time, topic will be on Informatics. Join us at the auditorium in Armauer Hansens Hus at 11:30 - 13:00 (lunch from 11:30 - 12:00).

**Speaker:** Gonzalo Sanchez Nido

**Topic:** Informatics

**Title:** to be announced

**Place:** The auditorium in Armauer Hansens Hus

**Time:** Wednesday June 21 at 11:30 - 13:00 (lunch from 11:30 - 12:00).

**Registration link:** [is available here](#)



# NEURO-SYSMED SEMINAR

## SEPTEMBER 13 - MATHIAS ZIEGLER

This time, topic will be on Metabolics. Join us at the auditorium in Armauer Hansens Hus at 11:30 - 13:00 (lunch from 11:30 - 12:00).

**Speaker:** Mathias Ziegler

**Topic:** Metabolics

**Title:** to be announced

**Place:** The auditorium in Armauer Hansens Hus

**Time:** Wednesday September 13 at 11:30 - 13:00 (lunch from 11:30 - 12:00).

**Registration link and abstract:** will be [available here](#)



## NEURO-SYSMED ANNUAL SYMPOSIUM, SEPTEMBER 25-26, SOLSTRAND HOTEL

Neuro-SysMed has the pleasure of inviting you to the 1st Neuro-SysMed Annual Symposium September 25-26 at Hotel Solstrand, and we ask you to save the date. We will invite a range of national and international speakers, and the symposium will have a scientific agenda which we will forward to you later. Confirmed speakers include: Vilhelm Bohr, Raymond Koopmans, and Kailash Bhatia, amongst others.

Our PhD candidates enrolled in the research school and NEUROSYSM920 Seminars and Symposium will have the opportunity to hold poster presentations as well as a 3-minute presentation.

Please pay attention to the following conditions:

- The subsidized registration fee is 3000 NOK per person for the two days and one overnight stay with full board.
- In order to enable us to accommodate 170+ participants in the 100 rooms available, we are dependent upon as many as possible sharing rooms (up to four).

Registration information with abstract submission guidelines will follow in the coming weeks.

**SAVE THE DATE!**



Later events can be found in [the Neuro-SysMed calendar](#).



# WELCOME TO NEW FACES IN THE NEURO-SYSMED GROUPS



**Suraj Sharma** has a background from India with studies in chemical engineering and technology, and a PhD from Germany where he developed mathematical models of glucosinolate biosynthesis. His research interests include kinetic modelling, metabolic modelling, metabolic pathway analysis, metabolic network analysis, systems medicine, AI and advanced data analytics. A special focus is on NAD, and Sharma has built mathematical models of human metabolism that can capture the role of NAD in metabolic alterations in the context of several types of cancers. As a researcher at Neuro-SysMed, he aims to integrate multi-omics data to develop mathematical models of human metabolism that can analyse the entire metabolome and identify disease-related metabolic changes, which can be used for patient stratification and clinical decision support.



**Sam Anandhan** holds an MS biotechnology, and a PhD from CCBIO/UiB, which focused on single cell mass cytometry by time of flight (CyTOF), with prospective exploration of novel biomarkers in ovarian cancer. Currently, she is pursuing her postdoc on MS at NeuroSysMed and is closely associated with the Myhr, Gavasso and Vedeler groups. Her project aims at establishing unique blood-based exosomal biomarkers for personalized anti-CD20 therapy in multiple sclerosis. She is also academic responsible and scientific coordinator at the NeuroSysMed Research School (for NEUROSYSTEM920/910) and the K.G. Jebsen Multiple Sclerosis Research Centre.



**Anna Rubiolo** is a new PhD student since February in the PD node. She holds a Bachelor's degree in Biological Sciences from the University of Turin in 2019 and a Master's degree in Neuroscience from the University of Trieste in 2022. During her Master, she was awarded an Erasmus+ Scholarship to study at the University of Helsinki, where she developed her Master's thesis studying how antidepressants and psychedelics induce cortical plasticity. In Professor Tzoulis' group, her research focuses on the role of mitochondrial dysfunction in the stratification of idiopathic Parkinson's disease.



**Heloisa Galbiati Belmonte** has an MSC and a PhD in Microbiology. Her interest in laboratory management grew 8 years ago, when she worked as a lab manager in a research institute (Sars Center) and later in a startup biotech company (Ocean Tuning Cell AS). Besides being responsible for both research and administrative tasks in her previous jobs, Heloisa had the unique opportunity to help plan and establish a new laboratory from scratch, strengthening her laboratory management skills. Heloisa joined the Neuromics group in 2023 as a Lab Manager for the K.G Jebsen Center and will be responsible for operational daily tasks, connecting research and administration within the group.



**Vegar Løland** is the new controller for NSM. He has worked at Helse Bergen since 2017 and has experience from different departments and various externally funded research projects at the hospital.



# RECENT NEURO-SYSMED NEWS STORIES

Psykologisk.no, 09.05.2023, "[Norsk forsker studerer hvordan sensorteknologi kan forutsi døden](#)"; Bettina Husebø, field dementia.

Psykologisk

Nyheter · Meer ·

## Norsk forsker studerer hvordan sensorteknologi kan forutsi døden

Med økonomisk støtte fra det europeiske forskningsrådet (ERC), skal professor Bettina Husebø ved UiB undersøke hvordan omsorgsteknologi kan brukes til å gjenkjenne symptomer på personer med demens nærmere seg livets slutt.



LIVETS SISTE FASE: I dag finnes det flere teknologier som kan hjelpe til å gjenkjenne når demensnærmer seg døden. Foto: Trina Mørch/Schneider, Pexels.

På Høyden, 08.05.2023, "[ERC til Valen og Husebø](#)"; Bettina Husebø, field dementia.

Tidsskrift for Den norske legeforening, 04.05.2023, "[Behandling av motoriske symptomer ved Parkinsons sykdom](#)"; Ole-Bjørn Tysnes, field Parkinson's.

TV2, 03.05.2023, "[Håper dette kan hjelpe mot de dødeligste hjernegåtene](#)"; Frank Riemer, general field.

Bergens Tidende - Login, 17.04.2023, "[Kan B-vitamin bremse Alzheimers? Forskarer studerer hjernen til Magnus](#)"; Kristoffer Haugarvoll, Ragnhild Eide Skogseth and Vivian Skjeie, field Alzheimer's.



På den siste jobbreisen merka Magnus at noko var gale. – Det er som om alt du tenker på smuldrar opp.

På den siste jobbreisen merka Magnus at noko var gale. – Det er som om alt du tenker på smuldrar opp.

Publisert: 17. april



NRK Vestland, 30.03.2023, "[Stilte feil diagnose - Solfrid har ikke Parkinsons sykdom likevel](#)"; Charalampos Tzoulis, field Parkinson's.

Dagbladet (paper version), 25.03.2023, "Jeg kan savne hvordan alt var før. Friheten ved å bare ta på seg ei jakke og gå ut døra. Livet var så enkelt"; Ole-Bjørn Tysnes, field ALS.

KS, 23.03.2023, "[Helgetun – et boligprosjekt i særklasse](#)"; Bettina Husebø, field dementia.

Aldring og helse, 20.03.2023, "[Kan en ny vitaminpille gi lengre og friskere liv?](#)"; Charalampos Tzoulis, field Parkinson's and Alzheimer's.

Aldring og helse Nasjonalt senter Kompetanseheving Skalaer og tester Forskning Kjøp

## Kan en ny vitaminpille gi lengre og friskere liv?

Norske forskere prøver nå å behandle selve aldringen for å gi oss lengre og friskere liv, og håper at dette også kan motvirke blant annet hjernesykdommer som Parkinsons og Alzheimers sykdom.

Tekst: Jørund Løkkeberg-Eek, 20. mar 2023



Charalampos Tzoulis om aldring, Parkinson og behandling.

MedWatch, 15.03.2023, "[Slik skal Norge lykkes med desentraliserte kliniske studier](#)"; Kjell-Morten Myhr, general field. Same topic in [LMI 14.03.2023](#).

Khrono, 11.03.2023, "[Oppdaga at primærhelsetenesta er lite rigga for forskning](#)"; Marie Hidle Gedde Bettina Husebø, field dementia.

Dagbladet Pluss, 08.03.2023, "[Øker risiko for demens med 90 prosent](#)"; Bettina Husebø, field dementia.

KK, 05.03.2023, "[- Legene sa de kunne love meg at det ikke var ALS](#)"; Ole-Bjørn Tysnes, field ALS.

kk ARETS MAGASIN LIVET MITT MOTE OG FRØNNHET UNDERHOLDNING VINNER OG KRØNER PLUSS

## - Legene sa de kunne love meg at det ikke var ALS

Likevel hadde 21 år gamle Victoria på føtelsen at det var noe som ikke stemte.



ALS: Victoria var bare 21 år gammel da hun ble diagnostisert med den brutale sykdommen. Foto: Privat

Allers, 03.03.2023, "Slik minimerer du risiko for demens"; Bettina Husebø, field dementia.

Se og Hør EXTRA (paper version), 03.03.2023, "Gråt da han fikk beskjeden"; Kjell-Morten Myhr, field MS.


TV2, 03.03.2023, "[Håper dette kan hjelpe mot de dødeligste hjernegåtene](#)"; Frank Riemer, general field.

Fædrelandsvennen, 17.02.2023, "[Eivor trodde hun bare var sliten. Så oppdaget legene hva som var galt](#)"; Kjell-Morten Myhr, field MS. Same article in Stavanger Aftenblad (paper version) 18.02.2023, Bergens Tidende 18.02.2023 paper version, iTromsø Pluss 17.02.2023 and Romsdals Budstikke Pluss 17.02.2023.

Bergens Tidende - login, 14.02.2023, "[Hjernevasking](#)"; Charalampos Tzoulis, field: brain research in general. Same article in Fædrelandsvennen - login 13.02.2023, Stavanger Aftenblad - login 11.02.2023, A-magasinet 10.02.2023 and Aftenposten - login 09.02.2023.

Dagbladet Pluss, 12.02.2023, "[Victorias \(24\) dødsdom: Ingen vei tilbake](#)"; Ole-Bjørn Tysnes, field ALS.

NRK Oslo og Viken, 10.02.2023, "[Norske forskere vil bremse aldring: Håper vitaminkapsel kan være løsningen](#)"; Charalampos Tzoulis fields Parkinson's, Alzheimer's and ALS.



## Tror vitaminkapsel kan bremse aldring

Kan en liten vitaminkapsel gi oss et friskere og lengre liv? Det forsøker norske forskere nå å finne svar på.



Forskere undersøker nå om (blå) blå kapslene kan gi oss bedre helse og lengre liv. FOTO: JAN-ERIK WILHELM / NRK

TV2, 29.01.2023, "[ALS-pasient satte rekord med tankekraft](#)"; Ole-Bjørn Tysnes, field ALS.

Tidsskrift for Den norske legeforening, 20.01.2023, "[Nye sentre skal gi flere kliniske studier i Norge](#)"; Kjell-Morten Myhr, general field.

Bergensavisen Pluss, 10.01.2023, "[Kjetil \(58\) har hatt Parkinsons i 12 år: - Bokser for å holde sykdommen i sjakk](#)"; Charalampos Tzoulis, field Parkinson's.

Bergensavisen (paper version), 10.01.2023, "Anbefaler trening uansett"; Charalampos Tzoulis, field Parkinson's.

# RELEVANT CALLS FOR FUNDING

Here is an overview of the upcoming deadlines for funding, relevant to our Neuro-SysMed students and researchers. For more details, please check the links below, at the Medical Faculty's page on [External Funding Opportunities](#), or ask our research advisor Yamila Torres Cleuren. She can also give advice on grants and applications. ([yamila.torres.cleuren@helse-bergen.no](mailto:yamila.torres.cleuren@helse-bergen.no)). She can among other discuss relevant calls with you, guide your project concept and design, review your proposal for national and international funding sources, from draft to submission stage, and provide advice on implementation of cross-cutting issues into your project (gender perspectives, user involvement, innovation, RRI, etc).



## Horizon Europe and international funding

ERC Starting grant [Starting Grant | ERC](#) (europa.eu). 2-7 years after PhD. October 17th, 2023.

UiB course (June 12th-13th): [How to write competitive proposals for the ERC Starting and Consolidator Grants | Støtte til eksterntfinansierte prosjekter \(BOA\) | UiB](#)

## Horizon Europe / Health cluster

The [Health Cluster](#) of Horizon Europe aims at promotion of health and well-being of the Europeans. Here is a selection of upcoming calls, with *deadline September 19, 2023*:

- [Access to health and care services for people in vulnerable situations](#), 6 MIO EUR
- [Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders](#), 8 MIO EUR
- [Comparative effectiveness research for healthcare interventions in areas of high public health need](#), 7 MIO EUR
- [Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data source](#), 12 MIO EUR

## Michael J. Fox Foundation

(Parkinson's Disease) [Pre-clinical Therapeutics Pipeline Program](#). Open deadline during 2023.

## Norwegian Research Council

NFR [Infrastructure](#). 2-200 MIO NOK, 5 years. Establishment or upgrading of research infrastructure of national importance. Deadline: 21 June 2023 (sketch) / 15 November 2023 (full)

## Innovation Grants

Qualification – Research Commercialisation from Publicly Funded Research 2023. 2-300 000 NOK, 3-12 months. Open deadline. [Qualification – Research Commercialisation from Publicly Funded Research 2023](#) (forskingsradet.no)

## UiB

May 26th, 2023: Spire: seed funding for international collaboration and application writing. [SPIRE - SÅKORNSMIDLER | Forsknings- og innovasjonsavdelingen | UiB](#)

October 1st, 2023: Mobility grants for PhD and postdoctoral fellows with UiB funding: [Financial support for stays abroad for PhD candidates and Postdoctoral Fellows | Faculty of Medicine | UiB](#)

## Individual fellowships and personal grants

May 11th, 2023: [2024 HFSP Postdoctoral Fellowships | Human Frontier Science Program](#)

September 13th, 2023: MSCA postdoctoral fellowships: [MSCA Postdoctoral Fellowships 2023 | Marie Skłodowska-Curie Actions \(europa.eu\)](#)

Open deadline: EMBO postdoctoral fellowships: [Fellowships, grants and career support – Postdoctoral Fellowships – EMBO](#)

## Helse Vest

**September 15th 2023:** Main deadline for research applications. More info TBA. Types of applications: PhD, postdoctoral fellowships, clinical research fellowships, clinical career stipend, short projects, open project support. Guidelines from 2022: [Retningslinjer og skjema - Helse Vest RHF \(helse-vest.no\)](#)

Ongoing: Helse Vest funded postdoctoral fellowship candidates can apply for 6-12 months **mobility** grants.

## DID YOU KNOW...

Two films you should not miss:

### DEN SISTE FILMEN



A serious and terminal diagnosis changes filmmaker Petter Vennerøds life abruptly. He wants you to join him on his last film - but it's urgent. The illness in his head is taking his words and thoughts. Available only at the cinemas.

### STILL



Follows the life of beloved actor and advocate Michael J. Fox, exploring his personal and professional triumphs and travails, and what happens when an incurable optimist confronts an incurable disease. Release date: 12/05, Apple TV+

## OTHER CENTRE UPDATES

Since **Magnus Alvestad** left in October of last year, we have been without a dedicated administrative coordinator. Instead, our research advisor **Yamila Torres Cleuren** has taken on some of his duties in reporting and communicating with the Norwegian Research Council, with the assistance of our new controller **Vegar Løland**. In addition, **Nina Grytten Torkildsen** has taken on a larger role to coordinate the Research School and assist with purchases and invoicing at Haukeland. The Parkinson's disease team now also has a new lab manager, who will also assist in managing the group and with purchases.

## LEAVING THE TEAM

After more than 2 years onboard, **Kim Brügger** will leave Neuro-SysMed and the Neuromics group at the end of May. Thank you for everything and good luck in your new chapter!

## CONTACT

### Centre co-Directors

Kjell-Morten Myhr, Centre Director  
kjell-morten.myhr@helse-bergen.no

Charalampos Tzoulis, Centre Co-Director  
charalampos.tzoulis@helse-bergen.no

### Research Adviser

Yamila Torres Cleuren  
Yamila.cleuren@uib.no  
+47 55 58 54 31

### Research School Coordinator

Nina Grytten Torkildsen  
nina.agnethe.grytten.torkildsen@helse-bergen.no

### Communications Officer

Eli Synnøve Vidhammer  
eli.vidhammer@uib.no

### General inquiries

Post@neuro-sysmed.no


### Website

Neuro-sysmed.no

### Events calendar

<https://www.uib.no/en/neuro-sysmed/calendar>

## ORGANIZATION



Neuro-SysMed



Haukeland University Hospital

